Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: Is the combination required

American Journal of Gastroenterology

Volumn 106, Issue 1, 2011, Pages 78-80

  Arendt, Bianca M ^a   Allard, Johane P ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; PLACEBO;

COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW;

ANTIOXIDANTS; ASCORBIC ACID; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; ODDS RATIO; PYRROLES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAMIN A;

EID: 78650969341     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.310     Document Type: Review

References (25)

1. Foster T, BudoffM, Saab S et al. Atorvastatin and antioxidants for the treatment of non alcoholic fatty liver disease: the St Francis heart study randomized clinical trial. Am J Gastroenterol 2010;106:71-7 (this issue).
2. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83.
3. Speliotes EK, Massaro JM, Hoffmann U et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-87.
4. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
5. Patel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol 2009; 43: 970-4.
6. Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 667-88.
7. Musso G, Gambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
8. Van Hout G, van Heck G. Bariatric psychology, psychological aspects of weight loss surgery. Obes Facts 2009; 2: 10-5.
9. Socha P, Horvath A, Vajro P et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48: 587-96.
10. Ratziu V, Giral P, Jacqueminet S et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Th erapy (FLIRT) trial. Gastroenterology 2008; 135: 100-10.
11. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
12. Hyogo H, Tazuma S, Arihiro K et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
13. Hatzitolios A, Savopoulos C, Lazaraki G et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-4.
14. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA et al. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-7.
15. Antonopoulos S, Mikros S, Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-4.
16. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-6.
17. Mihaila RG, Nedelcu L, Fratila O et al. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology 2009; 56: 1117-21.
18. Nelson A, Torres DM, Morgan AE et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebocontrolled trial. J Clin Gastroenterol 2009; 43: 990-4.
19. Arad Y, Newstein D, Roth M et al. Rationale and design of the St Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. Control Clin Trials 2001; 22: 553-72.
20. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
21. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010; 25: 399-405.
22. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann NY Acad Sci 1992; 669: 7-20.
23. Maras JE, Bermudez OI, Qiao N et al. Intake of alpha-tocopherol is limited among US adults. J Am Diet Assoc 2004; 104: 567-75.
24. Schleicher RL, Carroll MD, Ford ES et al. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr 2009; 90: 1252-63.
25. Dietrich M, Jacques PF, Pencina MJ et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 2009; 205: 549-53.